MAPK3 and psychiatric disorder: Future advances in this field include the study of downstream targets of ERKs activation (receptors, ion channels and factors affecting protein synthesis, trafficking and degradation), as well as the evaluation of novel inhibitors of ERK1/2 pathway in the prevention or treatment of neurological and psychiatric diseases involving memory disorders.